After signing up, you'll start to receive regular news updates from us.
DSM Biologics and Crucell Announce Licensing Agreement with Medarex

Complete the form below to unlock access to ALL audio articles.
DSM Biologics and Dutch biotechnology company Crucell N.V. have announced a PER.C6® license agreement with biopharmaceutical company Medarex, Inc.
This license agreement allows Medarex to use the PER.C6® production platform in its antibody research. Financial details of the agreement were not disclosed.